The FDA has approved a groundbreaking new drug to slow the progression of Alzheimer's disease in its early stages, offering ...

Kearney physician Dr. Bradley Rodgers will soon offer Kisunla, the first drug proven to slow the early onset of Alzheimer’s.

The U.S. Food and Drug Administration on Thursday approved Roche's under-the-skin injection to treat patients with multiple ...

Clinical trials need to evolve screening criteria to include diverse patient groups as more Alzheimer's disease drugs become ...

Eli Lilly said it will spend $1.8 billion to boost production in Ireland of its popular diabetes and weight-loss drugs, along with ingredients for its recently approved Alzheimer’s treatment, Kisunla.

Researchers have discovered that Alzheimer's drugs Leqembi and Kisunla boost levels of a healthy form of protein in the brain, even as they reduce its more toxic form.

Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.

THURSDAY, Sept. 11, 2024 (HealthDay News) -- Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab ...

Hoping to skirt the slow pace of new drug development, researchers are leaning on AI to uncover fresh uses for known ...

If the European Medicines Agency takes an overly cautious approach to selecting specialists to advise on new medicines, ...

Leqembi, an Alzheimer's drug from Biogen and Eisai, faces hurdles with respect to reimbursement and diagnostic uncertainties, diagnostic test requirements and the need for regular brain scans, CNBC ...

The next generation of Alzheimer’s therapeutics is moving away from amyloid plaques and tau tangles, offering multiple ...